Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
Authors:
- 13 March 2014
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 28 (4) , 373-387
Abstract
Dimethyl fumarate (Tecfidera®) is a novel oral therapy that has recently been approved for the treatment of relapsing forms of multiple sclerosis (MS) and relapsing-remitting MS (RRMS). In preclinical studies, dimethyl fumarate exhibited anti-inflammatory and cytoprotective properties that are generally thought to be mediated via activation of the nuclear factor (erythroid-derived 2)-like 2 transcriptional pathway, which is involved in the cellular response to oxidative stress. In the large, double-blind, multinational, 2-year DEFINE and CONFIRM trials conducted in over 2,600 adult patients with RRMS, twice-daily oral dimethyl fumarate 240 mg was effective in reducing the proportion of patients with MS relapse at 2 years (primary endpoint of DEFINE) and the annualized relapse rate (primary endpoint of CONFIRM) compared with placebo, with reduced disability progression also observed with the drug versus placebo in DEFINE. Dimethyl fumarate also reduced disease activity measures relative to placebo in these trials, as assessed by magnetic resonance imaging. Dimethyl fumarate was generally well tolerated in patients with RRMS; adverse events that occurred more frequently in dimethyl fumarate than in placebo recipients included flushing and gastrointestinal events. The long-term efficacy and tolerability of dimethyl fumarate is currently being investigated in the ENDORSE trial, with interim results demonstrating that dimethyl fumarate was associated with continued efficacy for up to 4 years of treatment, with no new tolerability concerns. In conclusion, although more comparative data are needed to fully establish the relative efficacy and tolerability of dimethyl fumarate compared with other therapies, oral dimethyl fumarate is an important addition to the therapeutic options available for RRMS.Keywords
This publication has 48 references indexed in Scilit:
- Effects of dimethyl fumarate on neuroprotection and immunomodulationJournal of Neuroinflammation, 2012
- Multiple sclerosisJournal of Clinical Investigation, 2012
- Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cellsJournal of Experimental Medicine, 2011
- Oxidative damage in multiple sclerosis lesionsBrain, 2011
- The Anti-Inflammatory Effects of Dimethyl Fumarate in Astrocytes Involve Glutathione and Haem Oxygenase-1ASN Neuro, 2011
- Nicotinic acid– and monomethyl fumarate–induced flushing involves GPR109A expressed by keratinocytes and COX-2–dependent prostanoid formation in miceJournal of Clinical Investigation, 2010
- Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammationJournal of Neuroinflammation, 2010
- Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosisBiochemical Pharmacology, 2008
- Multiple sclerosisThe Lancet, 2008
- Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltrationClinical and Experimental Immunology, 2006